Drug profile · INN
anifrolumab
SAPHNELO
anifrolumab (SAPHNELO) is a interferon-alpha/beta receptor alpha chain antagonist. Associated with AstraZeneca.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04AG11
Patents linked 0
Pipeline programs 9
News articles 0
Drug details — anifrolumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 9
- Data quality
- 0.83
Quick answer
anifrolumab (SAPHNELO) is a interferon-alpha/beta receptor alpha chain antagonist. Associated with AstraZeneca.
Key facts
INN anifrolumab
Brand SAPHNELO
Mechanism Interferon-alpha/beta receptor alpha chain antagonist
Target Interferon alpha/beta receptor 1
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AG11
Originator AstraZeneca
Mechanism of action
Interferon-alpha/beta receptor alpha chain antagonist
Primary target: Interferon alpha/beta receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is anifrolumab?
anifrolumab (SAPHNELO) is a interferon-alpha/beta receptor alpha chain antagonist. Associated with AstraZeneca.
What is the brand name for anifrolumab?
SAPHNELO is a marketed brand name for anifrolumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.